Deciphera Pharma Stock Rises After Announcing Corporate Restructuring


Deciphera Pharmaceuticals Inc DCPH will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors.

  • Deciphera will implement an organizational restructuring that will result in a workforce reduction of approximately 140 positions. The restructuring is expected to affect U.S. employees across all areas of the organization.
  • The Company said it would focus resources on two candidates, vemseltinib and DCC-3116. 
  • Vemseltinib is in Phase 1/2 for tenosynovial giant cell tumor, and DCC-3116 is in Phase 1 for RAS/RAF mutant cancers combined with Mekinist (trametinib).
  • Deciphera is also streamlining its U.S. commercial operations. The Company will keep a limited commercial presence in Europe to commercialize Qinlock (ripretinib) in France and Germany.
  • Further clinical development of Qinlock will be discontinued, including the Phase 1b/2 MEK combination study, which was planned to start in Q4 of 2021.
  • Qinlock is approved in the U.S. as a fourth-line treatment for gastrointestinal stromal tumors.
  • The rebastinib program, which was expected to enter a Phase 3 study next year in patients with platinum-resistant ovarian cancer, has been discontinued.
  • Deciphera had cash, cash equivalents, and marketable securities of $392 million as of September 30, and the changes will extend its cash runway into 2024.
  • The Company expects to recognize a one-time cash charge in the fourth quarter of approximately $32 million.
  • Read Next: Why Did Deciphera Stock Plunge 70% Today?
  • Price Action: DCPH shares are up 8.05% at $8.32 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!